RedditBluesky
  • Home
  • Artificial Intelligence
  • Cryptocurrencies
  • Technology
  • Gold
  • Stocks
Home » News » Pfizer: Pandemic could last until 2023

Pfizer: Pandemic could last until 2023

Company investigating triple vaccine for children

Justin Wong (JW)October 5, 2026



Pfizer Inc. said Friday that the COVID-19 pandemic could spread until next year and announced plans to develop a three-dose vaccine regimen for children ages 2 to 16, which could delay the vaccine's approval .

The US pharmaceutical company spoke out at the time European countries were preparing for further travel and social restrictions and a study warned that the fast-spreading variant of the Omicron coronavirus is five times more likely to get infected again than its predecessor Delta.

Pfizer (NYSE: PFE) officials said the company anticipates the disease will be endemic worldwide by 2024, meaning it will no longer be a pandemic. The company forecast that "COVID may become endemic by 2024".

Before the Omicron variant, leading US disease doctor Anthony Fauci predicted the end of the pandemic in the United States in 2022.

Announcing plans to develop a three-dose regimen for people ages 2 to 16, Chief Scientific Officer Mikael Dolsten said on a conference call that results from three doses in people over the age of 16 showed that this approach was greater Offer protection.

"So we decided to modify each of the pediatric studies to include a third dose in the series and apply for approval for a series of three doses instead of the two-dose series as originally intended," the company said.

Pfizer developed its COVID-19 vaccine together with German BioNTech SE (NASDAQ: BNTX). The companies have developed a version of their vaccine tailored to combat the Omicron variant, but have not yet decided whether it is needed. They expect to begin a clinical trial for the updated vaccine in January, Pfizer executives said.

The risk of re-infection with the Omicron variant is 5.4 times higher and there is no evidence that it is milder than the Delta variant, according to a study by Imperial College London, while cases are spreading across Europe Soaring high and threatening the end of the year festivities.

Previous infection may only offer 19% protection against re-infection with the new variant, according to Imperial College, which noted that the study, which included hundreds of thousands of cases, including 1,846 confirmed Omicron cases, has not been peer-reviewed was.

STEPS TO MORE RESTRICTIONS

The new evidence could make countries' efforts to speed up booster vaccinations to reduce the burden on hospitals and health systems even more urgent. So far, the surge in infections in the UK and other European countries has not resulted in a surge in hospital admissions or deaths.

Uncertainty about how Omicron's rapid expansion will affect global economic recovery was reflected in the mixed attitudes of major central banks this week.

The Bank of Japan maintained its ultra-loose monetary policy on Friday despite scaling back pandemic emergency funding.

Germany, Ireland, Switzerland and Denmark have all introduced further travel restrictions, following the example of France, which this week closed its borders to most of the immobile Brits.

Switzerland will extend the requirement to provide proof of vaccination or recovery from coronavirus to enter indoor spaces such as restaurants from Monday to January 24th, while a negative test result will be required in discos and bars.

Since the new variant is responsible for a fifth of the daily cases, the Danish government proposed to close theaters, cinemas, amusement parks and conference centers and to limit the public traffic in shops and stores only seven days before Christmas Eve.

"The rules of the game were changed again in record time," Prime Minister Mette Frederiksen told reporters. "It is not a question of a complete shutdown of society, as we saw last winter. Our goal is still to keep society as open as possible."

In Denmark, almost 3,000 Omicron infections were registered in the 24 hours up to Thursday evening - double the previous day - while the daily total number of infections hit a new record. The Danish Parliament has yet to approve the proposed restrictions before they can be implemented.

Irish Deputy Prime Minister Leo Varadkar said that given the "cruel virus", his government had no choice but to consider unpopular measures, including early bar and restaurant closings.

According to the rules, which could be announced on Friday, travelers from Great Britain to Germany would have to stay in quarantine for two weeks, said a spokesman for the German Ministry of Health.

INCREASING NUMBERS OF DEATHS

Since the coronavirus hit Wuhan, China nearly two years ago, more than 5 million people have died of COVID-19 worldwide and more than 272 million cases have been reported.

More than 8.5 billion doses of COVID-19 vaccine have been administered worldwide - an endeavor that the appearance of Omicron has made difficult.

The variant has driven infections in the UK close to the peak reached in early 2021, although the number of hospital admissions and deaths remains significantly lower. Infections also skyrocketed in December in European countries and the United States.

The governments of the European Union have agreed to order over 180 million doses of the modified version of the vaccine developed by BioNTech and Pfizer, according to the head of the EU executive body, the European Commission.

PfizerPandemie





Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.


Claw and Order: Antimony Rules the Resource Realm
Read Next

Claw and Order: Antimony Rules the Resource Realm

  • RIDE THE BULL

    Your Front Row Seat to the Stories That Move Markets. – Subscribe Now to our Newsletter!

  • Trending Now

    • Mark Carney Single-Outs NexGen's Rook 1 as a Critical Project of National Interest
      Mark Carney Single-Outs NexGen's Rook 1 as a Critical Project of National Interest
    • Skyharbour Resources Advances Nasdaq Aspirations with Fresh Athabasca NI 43-101 Filings
      Skyharbour Resources Advances Nasdaq Aspirations with Fresh Athabasca NI 43-101 Filings
    • Amazon Inks 20-Year Deal with Constellation to Expand Clean Nuclear Capacity
      Amazon Inks 20-Year Deal with Constellation to Expand Clean Nuclear Capacity
    • Four for Four: Super Copper Logs Visible Copper at El Alto Target in Atacama
      Four for Four: Super Copper Logs Visible Copper at El Alto Target in Atacama

Claim Your Spot with Juniorstocks.com

Unlock the stories that move markets directly in your inbox


ContactDisclaimerData PrivacyTerms of Use
  • Bluesky
  • Reddit
Copyright 2026 ©Juniorstocks.com - All Rights Reserved.